Dr. Zhang brings to Biosion over 25 years of biopharmaceutical experience in the clinical development strategy and operations of oncology drug programs in China and APAC region, including 11 years in Quintiles (now IQVIA). She successfully led key clinical development aspects of a number of innovative oncology assets, including a PD-1 mAb, PARP inhibitor and BRAF inhibitor, amongst others, into China and APAC markets.

Prior to joining Biosion, Dr. Zhang was Clinical Development Director, APAC, and Country Medical Director at Pierre Fabre Medicament. She has a track record of establishing and leading teams including functions consisting of clinical operations, project management and medical and pharmacovigilance to execute clinical development plans.

Before Pierre Fabre, Dr. Zhang was the Chief Medical Officer for Quintiles in the Greater China region. She helped to build the organization from 120 employees to 2,100 employees and built a new local subsidiary (Kuntuo) to complement the Company’s robust business growth. She enhanced strategic partnerships with top hospitals, key opinion leaders and medical associations in China. She led the Center of Clinical Excellence team to provide medical & scientific input for more than 30 due diligence licensing efforts to help local and global pharmaceutical companies develop and register products in the Greater China region.

Dr. Zhang has presented at many national and international drug development and Medical Affairs conferences, symposiums, and workshops. She served as an advisory board member of Chinese Society of Clinical Oncology (CSCO) for Clinical Research and Drug Safety, adding her substantial insights and experience in clinical development.

Dr. Zhang holds a M.D. in Clinical Medicine from Shanghai Jiao Tong University in China, and a M.B.A. from Cardiff University in the United Kingdom.